This paper describes a pathway of cholic acid synthesis, in man and in the rat, which involves 25-hydroxylated intermediates and is catalyzed by microsomal and soluble enzymes. The subcellular localization, stereospecificity, and other properties of the enzymes involved were studied with liver fractions of normolipidemic subjects, cerebrotendinous xanthomatosis patients, and rats. 5beta-Cholestane3alpha,7alpha,12alpha,25-tetrol was converted to 5beta-cholestane3alpha,7alpha,12alpha,24beta,25-pentol by the microsomal fraction in the presence of 7alpha,12alpha,24alpha,7alpha,12alpha,7alpha,12alpha,25, were also formed. In the presence of NAD, 5beta-cholestane-3alpha,7alpha,12alpha,24beta,25-pentol, but not the other 5beta-cholestanepentols formed, was converted to cholic acid by soluble enzymes in good yield. These experiments demonstrate the existence of a pathway for side-chain degradation in cholic acid synthesis which does not involve hydroxylation at C-26 or the participation of mitochondria.
INTRODUCTION
In the formation of cholic acid from cholesterol in mammalian liver, the ring system is probably hydroxylated first, forming 5P-cholestane-3a,7a,12a-triol (1) . As far as is known at present, the initial reaction in the side-chain oxidation is a 26-hydroxylation of 5#-cholestane-3a,7a,-12a-triol (I, Fig. 1 ) (1) (2) (3) (4) . The further oxidation of 5I-cholestane-3a,7a,12a,26-tetrol (II) leads to formation of 3a,7a,l2a-trihydroxy-5fi-cholestan-26-oic acid (III) Received for publication 6 October 1975 and in revised form 15 December 1975. (5) which in turn is converted into cholic acid (V) via varanic acid, 3a,7a,12a,24t-tetrahydroxy-5f8-cholestan-26-oic acid (IV) (6, 7).
Recent work in this and other laboratories has indicated that the degradation of the cholesterol side chain to cholic acid may involve intermediates hydroxylated at C-25. Of particular importance in this respect are the findings by Cronholm and Johansson in the rat (2) and by Bjorkhem et al. in man (8) that the major product formed during the incubation of 5,8-cholestane-3a,7a,12a-triol with liver microsomes was 5Pt-cholestane-3a,7a,12a,-25-tetrol and not 5,3-cholestane-3a,7a,12a,26-tetrol. Our own studies have shown that patients with cerebrotendinous xanthomatosis (CTX)' accumulate 25-hydroxylated bile alcohols in bile and feces (9) , and that 5f-cholestane-3a,7a,12a,25-tetrol is transformed into cholic acid both in CTX patients and in normolipidemic subjects (10) , a result previously reported by Yamada in the rat (11) . While it was known, therefore, that 5j-cholestane3a,7a,12a-triol can be converted to 5,8-cholestane-3a,7a,-12a,25-tetrol in vitro and that the latter could be metabolized to cholic acid in vivo, the individual steps of this pathway remained to be demonstrated.
In the present study it was shown that in man and in the rat, liver microsomal enzymes catalyze the 249-hydroxylation of 5#-cholestane-3a,7a,12a,25-tetrol (VI, Fig.   2 ) and that the resultant 5i9-cholestane-3a,7a,12a,24i9, 25- pentol (VII) is rapidly transformed into cholic acid (V)
by soluble enzymes. Since 5,8-cholestane-3a,7a,12a-triol (I) is converted to 5,8-cholestane-3a,7a,12a,25-tetrol by a microsomal system (2), the pathway of cholic acid 1Abbreviations used in this paper: CTX, cerebrotendinous xanthomatosis; GLC, gas-liquid chromatography; TLC, thin-layer chromatography; TMSi, trimethylsilyl. Preparation of unlabeled compounds. 5fi-Cholestane-3a, 7a,12a,25-tetrol (mp 189-191'C) was prepared from cholic acid and purified as described by Dayal et al. (13) . 5,-Cholestane-3a,7a,12a,24a,25-pentol (IX, Fig. 3 ) (mp 212-214°C) and 5p-cholestane-3a,7a,12a,24fi,25-pentol (VII) (mp 203-205'C) were synthesized from 5fi-cholestane-3a, 7a,12a,25-tetrol as described previously (13, 14) . 5p-Cholestane-3a,7a,12a,25,26-pentol (X) (mp 182-184°C; lit mp 178.5'C [15] ), was obtained during the synthesis of 59-cholestane-3a,7a,12a,24t,25-pentol (13) 5j3-Cholestane-3a,7a,12a,23C,25-pentol (VIII, Fig. 3 ) (mp 210-211'C) was isolated from the feces of CTX patients, purified, and crystallized as previously described (14) .
Preparation of labeled compounds. [G-'H]5p-Cholestane3a,7a,12a,24a,25-pentol, [G-3H] 5f-cholestane-3a,7a,12a,24#, 25 -pentol, and [G-'H]5fi-cholestane-3a,7a,12a,23t,25-pentol (5 mg of each) were tritiated by the Wilzbach procedure at New England Nuclear, Boston, Mass. (17) , and purified by column and thin-layer chromatography (TLC), (13, 14) to constant specific radioactivity. The following specific activities were obtained: 24a-epimer, 1.78 X 10' dpm/nmol (radiopurity, 94.8%); 24#-epimer, 1 .36 X 10' dpm/nmol (93.7% pure); and 5f-cholestane-3a,7a,12a,23t,25-pentol, 1.86 X 10' dpm/nmol (radiopurity, 92.4%).
[G-3H]5f-Cholestane-3a,7a,12a,25,26-pentol was prepared enzymatically by incubating [G-3H]5fi-cholestane-3a,7a,12a, 25 -tetrol with rat liver microsomes as described in the section entitled "Enzyme Assays" (see below). 5#-Cholestane-3a,7a,12a,24a,25-pentol and 5fi-cholestane-3a,7a,12a, 25 
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Shefer, Cheng, Dayal, Hauser, Tint, Salen, and Mosbach spectively. The latter was identified by gas-liquid chromatography (GLC) (14) and mass spectrometry. Its mass spectrum was identical with that of the synthetic 5#-cholestane-3a,7a,12a,25,26-pentol, described above. The specific radioactivity was 0.8 X 104 dpm/nmol and the radiopurity was 96.1%o. Cofactors. NAD and NADPH were purchased from Calbiochem, La Jolla, Calif.
GLC. The 5#-cholestanepentol fraction was analyzed as the TMSi derivatives on 180 X 0.4-cm columns packed with 3% QF-1 on 80-100 mesh Gas-Chrom Q (Applied Science Laboratories, Inc., State College, Pa.), column temperature 2300C (model 7610 gas chromatograph, Hewlett-Packard Co., Palo Alto, Calif.). The retention times relative to 5fi-cholestane were described previously (14) .
Mass spectra. Mass spectra of the bile alcohols were obtained with a Varian MAT-111 gas chromatograph-mass spectrometer (Varian Associates, Palo Alto, Calif.) as described previously (14) .
Methods

FRACTIONATION OF LIVER HOMOGENATES
All specimens of human liver were obtained at about 10 :00 a.m. to minimize the diurnal variation in bile acid synthesis. The liver tissue was placed immediately in icecold 0.1 M Tris-Cl buffer, pH 7.4, containing 2.5 mM EDTA and was transported to the laboratory in an ice bath within 1 h.
In animal experiments, rats were killed by cervical dislocation and the liver was removed immediately and chilled on ice. All subsequent operations with human or rat liver were carried out at 0-4°C. The liver was extruded through a tissue press (Harvard Apparatus Co., Millis, Mass.). A 1-g aliquot was homogenized in a loose-fitting PotterElvehjem homogenizer with 4 ml of 0.1 M-Tris-Cl buffer, pH 7.4, containing 2.5 mM EDTA. The homogenate was centrifuged for 12 min at 800 g, and nuclei and cell debris were discarded. The microsomal fraction was obtained by centrifuging the 800-9 supernatant solution for 12 min at 20,000 g followed by centrifugation at 100,000 g for 1 h (18). The microsomal pellet was washed by resuspension in 0.1 M Tris-Cl buffer, pH 7.4, with EDTA, and centrifugation for 1 h at 100,000 g. The final pellet was suspended in 0.1 M Tris-Cl buffer, pH 7.4, with EDTA in a volume corresponding to the original 20,000-g supernatant solution from which it had been prepared. The mitochondrial fraction was obtained by resuspension of the 20,000 g pellet in 0.25 M sucrose and centrifugation at 8,500 g for 12 min (19) . A more highly purified mitochondrial fraction was obtained by following the procedure of Wilgram and Kennedy (20) . This method results in a fraction of intact mitochondria with minimal microsomal contamination. The final mitochondrial pellet was suspended in half the volume of the original 20,000-g supernatant solution with 0.1 M Tris-Cl buffer, pH 7.4, with EDTA. When it was desired to carry out incubations with ruptured mitochondria, the method of Taniguchi et al. (21) was employed.
Protein was determined according to Lowry et al. (22) . The protein content of the microsomal fraction was about 5 mg/ml; of the mitochondrial fraction, about 3 mg/ml; and of the 100,000-g supernatant fraction, about 12 mg/ml. ENZYME ASSAYS Conversion of 5,-cholestane-3a,7a,12a,25-tetrol to S,8-cholestanepentols. 5,s-Cholestane-3a,7a,12a,25-tetrol (2 , Imol) in methanol was mixed with 1. (14) . Two major bands were obtained (R, = 0.30 and Rr 0.32-0.34), which were made visible with iodine vapor. The bands at Rr 0.30 (5#-cholestane-3a,7a,12a,24a,25-pentol + 5#-cholestane-3a,7a,12a,25,26-pentol) and at Rr 0.32-0.34 (5fi-cholestane-3a,7a,12a,24B,25-pentol + 5jB-cholestane-3a,7a,12a,23t,25-pentol) were removed separately from the plate and eluted with methanol. The solvent was evaporated under N2, and the composition of each band was determined by GLC and confirmed by GLCmass spectrometry (14) . Retention time of TMSi ethers relative to 5a-cholestane were: 5#-cholestane-3a,7a,12a,23E, Conversion of 5j9-cholestane-3a,7a,12a,24,8,25-pentol to cholic acid. In standard incubation procedures 200 nmol of the tritiated substrate were dissolved in 30 pl of acetone which was quickly dispersed into 0.2 ml of 0.1 M Tris-Cl buffer, pH 7.4. The incubation medium contained in a volume of 0.72 ml: 83 mM Tris-Cl buffer, pH 7.4; 4.2 mM NAD+; 100,000-g supernatant solution containing approximately 0.5 mg of protein. The incubation was carried out by shaking in air at 37°C for 10 min. The reaction was terminated by addition of 1 ml of 2% NaOH in 95% ethanol. After addition of 1 ml water the unreacted substrate was extracted three times with 4 ml ethyl acetate. The remaining water layer was cooled on ice, acidified (pH 2) with 6 25-Hydroxylation in Cholic Acid Biosynthesis 899 
RESULTS
Conversion of 5f-cholestane-3a,7a,12a,25-tetrol to 5P-cholestanepentols. Table I illustrates the composition of the 5P-cholestanepentol fractions obtained from incubation of 5,-cholestane-3a,7a,12a,25-tetrol with hepatic microsomal fractions of normolipidemic subjects, CTX patients, and rats. In man the major product (approximately 40%) was 5B-cholestane-3a,7a,12a,24%,25-pentol with lesser amounts of 5fi-cholestane-3a,7a,12a,24a,25-pentol, 5p-cholestane-3a,7a,12a,23t,25-pentol, and 5p-cholestane-3a,7a,12a,25,26-pentol (Fig. 3) . In the rat relatively larger amounts of the 24a-epimer were produced than in man.
The subcellular distribution of the hydroxylation system which catalyzes the conversion of 5p-cholestane-3a,-7a,12a,25-tetrol to cholestanepentols is shown in Table   TABLE I II. It was found that the hydroxylation was catalyzed predominantly by the microsomal fraction.
The side-chain hydroxylation of 5#-cholestane-3a,7a,-12a,25-tetrol required NADPH and 02. The activity was greatly reduced when NADH was the electron donor or when oxygen was absent as illustrated in Table III .
Conversion of 5P-cholestane-3a,7a,12a,24P,25-pentoI to cholic acid. Table IV illustrates the subcellular distribution of the enzyme system which transforms 5#-choles- 5fB-Cholestane-3a,7a,12a,24a,25-pentol. § 513-Cholestane-3a,7a,12a,24i3,25-pentol.
Partially broken mitochondria (21).
tane-3a,7a,12a,24,25-pentol to cholic acid. The two pentols epimeric at C-24 were used as substrates.
The results demonstrate that the enzyme system is located predominantly in the soluble fraction and that the 24P-epimer is the preferred substrate for cholic acid formation. It was found in these experiments that only free, i.e. unconjugated, cholic acid was formed, since alkaline hydrolysis (120°C, 3 h, 10% NaOH [wt/vol]) liberated no additional amounts of cholic acid. Additional data on the substrate specificity of the enzyme system are shown in Table V . 5fi-Cholestane-3a,7a,-12a,24,f,25-pentol was the only substrate tested which was transformed into cholic acid at a rapid rate. The rate of production of acidic material from the other iso- The requirement of the cholic acid-forming enzyme system for NAD is shown in Table VI. The enzyme was inactive in the absence of NAD+ but 10-15% of the total activity was restored in the presence of excess NADP+.
To identify and establish the radioactive purity of the biosynthetic cholic acid the assay system described in the Methods section was scaled up about 10-fold and the labeled cholic acid formed was extracted and separated by TLC. The cholic acid band was visualized with iodine vapor and eluted with methanol. The identity and radioactive purity of the biosynthetic cholic acid was determined by reverse isotope dilution of the free acid and two derivatives, as shown in radioactivity of the biosynthetic cholic acid remained constant within the precision of measurement (±7%).
DISCUSSION
The results of the present paper demonstrate that 5#-cholestane-3a,7a,12a-triol can be converted to cholic acid in human and rat liver in vitro, via a 25-hydroxylation pathway (Fig. 2) , without the participation of 26-oxygenated derivatives. Incubation of 5#-cholestane-3a,7a,-12a,25-tetrol with the microsomal fraction under the conditions employed resulted in the formation of a mixture of 59-cholestanepentols. When microsomes prepared from human liver, either from normolipidemic controls or CTX patients, were used, 5P-cholestane-3a,7a, 12a,24P, 25-pentol was the predominant component, while with rat liver microsomes 5fl-cholestane-3a,7a,12a,24a,25-pentol and 5f-cholestane-3a,7a,12a,24fl,25-pentol were formed in equal amounts and constituted the major products formed (Table I) . The 25-hydroxylation pathway of cholic acid biosynthesis, just like the one proceeding via 26-hydroxylated intermediates, involves the introduction of a hydroxyl group at C-24. It seems, however, that the enzymes which carry out the 24-hydroxylation are not similar for the two pathways, suggesting that different mechanisms are involved. In the 25-hydroxylation pathway, the reaction is catalyzed solely by a microsomal enzyme which was not stimulated by the addition of 100,000-g supernatant solution. Mitochondria and 100,000-g supernatant solution, either alone or in combination did not catalyze the formation of 24-hydroxylated 5#-cholestanepentols (Table II). In contrast, Masui and Staple and, more recently, Gustafsson found that the introduction of the C-24 hydroxyl group into 3a,7a,12a-trihydroxy-5P-cholestan-26-oic acid (III, Fig. 1 ) was catalyzed either by the mitochondrial fraction (6, 24) or by the microsomal fraction fortified with 100,000-g supernatant solution.
In the case of the microsomal fraction large amounts of ATP were required (24) . Moreover, the 24-hydroxylation of 5fl-cholestane-3a,7a,12a,25-tetrol (II, Fig. 2 ) requires O and NADPH (Table III) and is probably catalyzed by a mixed function oxidase, although the participation of cytochrome P-450 was not investigated by us. Recent studies by Gustafsson (24) postulated that in the pathway involving 26-oxygenated intermediates the 24-hydroxylation step was not catalyzed by a mixed function oxidase but was analogous to fatty acid P-oxidation and involved an acyl dehydrogenase and enoyl hydrase as had also been suggested by Masui and Staple (6) .
In the present studies, the rate of 5fl-cholestanepentol formation was considerably higher in rat than in human liver microsomes. Hydroxylation was about four times greater in the human control subjects than in the CTX patients (Table II) . The reduced rate of 24P-hydroxylation is presumably due to a relative deficiency of this hydroxylase in CTX patients as compared to the controls and may explain the accumulation of 5#-cholestane3a,7a,12a,25-tetrol in bile and feces of the former (9). It seems unlikely that the observed difference was due to differences in tetrol concentration in the microsomal preparations since the amount of tetrol present in the microsomes was found to be negligible in comparison to the amount of substrate added to saturate the enzyme. It is therefore conceivable that the relative lack of this 240-hydroxylase represents a major metabolic defect in CTX.
The enzyme catalyzing the transformation of 5fl-cholestane-3a,7a,12a,24,25-pentol to cholic acid was located predominantly in the 100,000-g supernatant fraction (Table IV). This transformation proceeded at approximately equal rates in man and in the rat. In both species the reaction appeared to be quite stereospecific in that only the 24fl-epimer was transformed to cholic acid at an appreciable rate (Table V) . This stereospecificity and the rapid metabolism of the 24fl-epimer to cholic acid might explain the fact that only 5,8-cholestane-3a,7a,12a,23t,25-pentol and 5p-cholestane-3a,7a,12a,24a,25-pentol could be detected in bile and feces of CTX patients. We were unable to find 5fl-cholestane-3a,7oa,12a,24f8,25-pentol, presumably because it was rapidly transformed into cholic acid (14) . The soluble enzyme system required NAD'
for the formation of cholic acid (Table VI) . The reaction might involve a 24-ketone intermediate, which was however not observed in the present study. Until further work has been done it may be speculated that the desmolase which catalyzes cleavage of the side chain between carbons 24 and 25 is a dehydrogenase/hydroxylase as has been postulated for the mechanism of adrenal hormone synthesis (25) . Thus, the results of the present study suggest that there exists an alternate pathway of cholic acid biosynthesis in man and in the rat involving the 25-hydroxylation of 59-cholestane-3a,7a,12a-triol (I, Fig. 2 ). This pathway proceeds via 5j-cholestane-3a,7a,12a,25-tetrol (VI) and 51-cholestane-3a,7a,12a,24P,25-pentol (VII) and does not involve 53-cholestanoic acids as intermediates. While it is known that the 25-hydroxylation pathway is important in the formation of cholic acid in patients with CTX, the quantitative significance of 25-hydroxylation of 5fi-cholestane-3a,7a, 12a-triol for cholic acid synthesis in normal man and in the rat remains to be evaluated.
